[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].

Zhonghua yi xue za zhi

PubMedID: 25547700

Sheng X, Kong Y, Tang H, Lian B, Mao L, Chi Z, Cui C, Si L, Wang X, Yan X, Li S, Dai J, Guo J. [Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib]. Zhonghua Yi Xue Za Zhi. 2014;94(38):2988-91.
OBJECTIVE
To explore the genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with metastatic clear-cell renal cell carcinoma (mcc-RCC) treated with sunitinib.

METHODS
A total of 93 mcc-RCC patients treated with sunitinib were enrolled. Genotype analyses were performed before treatment and thrombocytopenia was recorded on the first three cycles of treatment. Genetic polymorphisms of PDGFR (rs35597368, rs1800810) were analyzed for a possible association with thrombocytopenia.

RESULTS
The genotypes of rs35597368 and rs1800810 conformed to the Hardy-Weinberg law. No significant difference existed in grade 3/4 thrombocytopenia between rs35597368 TC and TT genotypes (29.6% vs 29.4%, P = 0.313). The rs1800810 CG genotype was associated with a higher risk for grade 3/4 thrombocytopenia as compared with CC genotype (45.8% vs 34.2%, P = 0.048).

CONCLUSIONS
The risk for grade 3/4 thrombocytopenia increases in the presence of allele genotype in PDGFR 1171C/G. And a biomarker may be customized for patients with mcc-RCC treated with sunitinib.